Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 44Urinary Bladder Neoplasms 42Testicular Neoplasms 30Carcinoma, Transitional Cell 30Ovarian Neoplasms 28Testicular Germ Cell Tumor 16Carcinoma, Non-Small-Cell Lung 14Melanoma 11Kidney Neoplasms 11Carcinoma, Renal Cell 11Breast Neoplasms 11Wilms Tumor 10Urethral Neoplasms 10Teratoma 10Sarcoma 10Pancreatic Neoplasms 10Central Nervous System Neoplasms 10Colorectal Neoplasms 9Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Stomach Neoplasms 7Ovarian Germ Cell Cancer 7Neoplasms 7Seminoma 6Osteosarcoma 6Neuroblastoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Ureteral Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Carboplatin 2zimberelimab 1sirtratumab vedotin 1sacituzumab govitecan 1olaparib 1avelumab 1Oxaliplatin 1Nivolumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Urothelial Cancer × Carboplatin × Genitourinary × Clear all
NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡